Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...
Gene therapies that are based on adeno-associated virus (AAV) vectors have demonstrated immense potential to treat and even cure previously intractable diseases, but unfortunately the costs are ...
Pharmaron Biologics, Liverpool, UK, is a commercial development and manufacturing organization (CDMO) that offers a range of unique end-to-end laboratory services for the development and manufacture ...
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs. -- Virica and ...
VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...
HOLLISTER, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (TKNO), a leading producer of critical reagents for the research, discovery, development ...
Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...
New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...
Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results